Fowler Carol B, Pogozheva Irina D, Lomize Andrei L, LeVine Harry, Mosberg Henry I
Department of Medicinal Chemistry, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, USA.
Biochemistry. 2004 Dec 21;43(50):15796-810. doi: 10.1021/bi048413q.
Site-directed mutagenesis and design of Zn(2+)-binding centers have been used to determine a set of specific tertiary interactions between the mu-opioid receptor, a rhodopsin-like G protein-coupled receptor (GPCR), and its cyclic peptide agonist ligand, Tyr(1)-c(S-Et-S)[d-Cys(2)-Phe(3)-d-Pen(4)]NH(2) (JOM6). The binding affinity of the tetrapeptide is strongly dependent on the nature of its first and third residues and on substitutions at positions 213, 216, 237, 300, 315, and 318 of the mu-opioid receptor. His(1) and His(3) analogues of the ligand were able to form metal-binding complexes with the V300C and G213C/T315C receptor mutants, respectively. Direct contact of the Phe(3) residue of JOM6 with Gly(213), Asp(216), Thr(315), and Trp(318) of the receptor was suggested by the binding affinities of His(3)-, Nle(3)-, Leu(3)-, Aci(3)-, Delta(E)Phe(3)-, and Delta(Z)Phe(3)-substituted peptides with the G213C/T315C, D216V, T315C, and W318L mutants. The improved binding affinity of the free carboxylate analogue of JOM6 for binding to the E229D mutant revealed an interaction between the C-terminal group of the peptide and Glu(229) of the receptor. The experimental constraints that were obtained were applied for distance geometry modeling of the mu-receptor in complex with the tetrapeptide agonist ligand, JOM6. The active conformation of the opioid receptor was calculated using the crystal structure of "inactive" rhodopsin and published engineered and intrinsic metal-binding sites and disulfide bonds that allow or facilitate activation of GPCRs. Interhelical H-bonds existing in the mu-receptor were applied as additional distance constraints. The calculated model of the receptor-ligand complex can serve as a prototype of the active state for all rhodopsin-like GPCRs. It displays a strongly shifted transmembrane helix 6 (TM6) and reorientation of the conserved Trp(293) residue in TM6 upon its interaction with the agonist. Importantly, the binding pockets of the active and inactive states are not identical, which implies distinct interaction modes of agonists and antagonists. In the active state, the binding pocket of the mu-receptor is complementary to the previously proposed receptor-bound conformation of JOM6.
定点诱变和锌离子结合中心的设计已被用于确定μ-阿片受体(一种视紫红质样G蛋白偶联受体(GPCR))与其环肽激动剂配体Tyr(1)-c(S-Et-S)[d-Cys(2)-Phe(3)-d-Pen(4)]NH₂(JOM6)之间的一组特定三级相互作用。四肽的结合亲和力强烈依赖于其第一个和第三个残基的性质以及μ-阿片受体213、216、237、300、315和318位的取代情况。配体的His(1)和His(3)类似物能够分别与V300C和G213C/T315C受体突变体形成金属结合复合物。His(3)-、Nle(3)-、Leu(3)-、Aci(3)-、Delta(E)Phe(3)-和Delta(Z)Phe(3)-取代肽与G213C/T315C、D216V、T315C和W318L突变体的结合亲和力表明JOM6的Phe(3)残基与受体的Gly(213)、Asp(216)、Thr(315)和Trp(318)直接接触。JOM6的游离羧酸盐类似物与E229D突变体结合时结合亲和力的提高揭示了肽的C末端基团与受体的Glu(229)之间的相互作用。所获得的实验限制条件被应用于与四肽激动剂配体JOM6复合的μ受体的距离几何建模。使用“无活性”视紫红质的晶体结构以及已发表的工程化和内在金属结合位点和二硫键来计算阿片受体的活性构象,这些位点允许或促进GPCR的激活。μ受体中存在的螺旋间氢键被用作额外的距离限制条件。计算得到的受体-配体复合物模型可作为所有视紫红质样GPCR活性状态的原型。它显示出跨膜螺旋6(TM6)强烈移位,并且在与激动剂相互作用时TM6中保守的Trp(293)残基重新定向。重要的是,活性状态和非活性状态的结合口袋并不相同,这意味着激动剂和拮抗剂的相互作用模式不同。在活性状态下,μ受体的结合口袋与先前提出的JOM6的受体结合构象互补。